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Evaluation of anaemia in patients with
multiple myeloma and lymphoma: ﬁndings
of the European CANCER ANAEMIA
SURVEY
Anemia is a serious and common complication in
patients with non-Hodgkin’s lymphoma (NHL),
Hodgkin’s disease (HD), and multiple myeloma
(MM) (1–5). Moullet et al. (2) reported the
presence of anemia [hemoglobin (Hb) £ 12 g/dL
for all patients over age 50; £ 11 g/dL for women
under age 50] at diagnosis in 32% of 1077 patients
with non-Hodgkin’s disease (range 17–39%,
depending on histologic subtype), and Kyle et al.
(6) reported anemia (Hb £ 12 g/dL) in 73% of
1027 patients with newly diagnosed MM. Several
factors can cause anemia in patients with lym-
phoid malignancies or MM, including abnormal
iron utilization, inappropriately low serum ery-
thropoietin levels, a decrease of bone-marrow
response to erythropoietin, hemolysis, and bone-
marrow involvement (2, 7). However, anemia may
also be caused or exacerbated by treatment with
cytotoxic agents. Coiﬃer et al., in a retrospective
chart survey of patients with various solid or non-
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Abstract: Objectives: Until recently, no prospective epidemiologic
survey of lymphoma and multiple myeloma (L/MM) in European
cancer patients had been conducted; furthermore, data on prevalence,
incidence, and treatment patterns of L/MM were limited or
unavailable. Here we deﬁne anemia prevalence, incidence, and
treatment patterns, and identify anemia risk factors in European
L/MM patients. Methods: Data for a subgroup of 2360 L/MM
patients in the European Cancer Anaemia Survey (ECAS) were
analyzed; variables included age, gender, tumor type/stage, cancer and
anemia treatment, WHO performance status, and hemoglobin (Hb)
levels. Results: 2316 patients were evaluable (1612 L and 704 MM).
Anemia rate at enrollment was 52.5%. At enrollment, Hb levels
correlated signiﬁcantly with WHO scores (r ¼ )0.306, P < 0.001).
Anemia prevalence during ECAS was 72.9% (MM, 85.3%; non-
Hodgkin’s lymphoma, 77.9%; Hodgkin’s disease, 57.4%); incidence in
chemotherapy patients was 55.4%. Only 47.3% of patients anemic any
time during ECAS received anemia treatment; overall Hb nadir for
initiating treatment was 8.9 g/dL (epoetin, 9.5 g/dL; transfusion,
8.2 g/dL). Factors found to signiﬁcantly (P < 0.03) increase anemia
risk were low initial Hb, female gender, persistent/resistant disease, and
platinum chemotherapy. Conclusions: L/MM patients have a high
prevalence and incidence of anemia; however, anemia is not optimally
treated. Anemia is common in L/MM patients and, given its known
adverse impact on physical functioning and quality-of-life variables
including fatigue and cognitive function, anemia management should
be an integral part of their care. Predictive factors identiﬁed by ECAS
may help clinicians develop optimal anemia treatment strategies for
L/MM patients.
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378myeloid hematologic malignancies treated at 24
centers in France, found that the prevalence of
moderate anemia (Hb 8.0–<10.5 g/dL) in patients
with HD or NHL increased from 16.1% and
18.9% to 25.7% and 34.9%, respectively, at the
start of the fourth chemotherapy cycle (8). In a
recent publication, Ludwig et al. reported the
results of the European Cancer Anaemia Survey
(ECAS), which proﬁled cancer-related anemia in
the European cancer population-at-large (9). The
survey evaluated the prevalence, incidence, and
current treatment patterns of cancer-related ane-
mia, as well as its relationship to World Health
Organization (WHO) performance status and risk
factors for its development. A total of 15 317
patients from 748 centers in 24 European coun-
tries were enrolled and were followed for up to
6 months. The prevalence of anemia (Hb level
<12.0 g/dL) was found to be 39.3% at enrollment
and 67.0% during the survey; incidence of anemia
was 53%. Moreover, decreased Hb level was
found to correlate signiﬁcantly (P < 0.001) with
poor performance scores at enrollment (Pearson
r ¼ )0.24) and during the survey (range: Pearson
r ¼ )0.27 to )0.30).
It is now recognized that anemia may lead to
symptoms that adversely aﬀect physical status
and diminish functional capacity and quality of
life (QOL) in cancer patients (5, 10). Anemia may
also be associated with poorer prognosis and
increased patient mortality (2, 11–13). Because of
the importance of anemia in patients with hema-
tologic malignancies, data from patients with
lymphoma or multiple myeloma (L/MM) who
were included in the ECAS were analyzed. The
objectives of these analyses were to deﬁne the
prevalence and incidence of anemia in patients
with L/MM, elucidate the relationship between
anemia and performance status as measured by
WHO criteria, assess anemia treatment patterns,
and deﬁne risk factors for the development of
anemia in this patient subgroup. Results of the
analyses are described here.
Materials and methods
The methodology for ECAS has been described
elsewhere (9). Brieﬂy, ECAS was a large, pros-
pective, epidemiologic, observational survey con-
ducted in 748 academic, community, and private
centers specializing in cancer care in 24 European
countries. All procedures met local Ethical Com-
mittee requirements and were conducted in
accordance with the guidelines deﬁned in the
Declaration of Helsinki.
Patients enrolled were adults with a solid or
hematologic malignancy, irrespective of their dis-
ease status (newly diagnosed, persistent/recurrent,
in remission), type of cancer treatment (surgery,
chemotherapy, radiotherapy, hormone or immuno-
therapy, any combination of the preceding, or
none), or their treatment status. Additionally, these
patients had to be under the care of a physician or
center specializing in cancer treatment, but not
enrolled in a clinical trial.
Data were collected at enrollment, at up to six
evaluation points or monthly for up to 6 months
at regular scheduled clinic visits, and at survey
completion. Data collected at enrollment included
age, gender, tumor type and stage, date of initial
diagnosis, disease status, performance status, and
laboratory values (including Hb and hematocrit);
also, cancer treatment and anemia therapy [trans-
fusion, recombinant human erythropoietin (epo-
etin), and/or iron] within 30 d of survey
enrollment and at enrollment were recorded.
Data collected at follow-up included performance
status, laboratory values, cancer treatment, ane-
mia therapy, and current cycle number for
patients receiving chemotherapy. At survey com-
pletion, performance status, laboratory values,
ﬁnal chemotherapy and radiotherapy regimens,
and reason for survey completion (end of survey
period, death, lost to follow-up, early withdrawal)
were recorded. Performance scores were based on
the WHO scale, which ranges from 0 (best
possible score) to 4 (worst possible score).
Anemia was deﬁned as an Hb level <12 g/dL,
in accordance with the toxicity grading criteria
from the National Cancer Institute (NCI) and the
European Organization for Research and Treat-
ment of Cancer (EORTC). For statistical ana-
lyses, anemia was further categorized as 11.9–
10.0 g/dL (mild), 9.9–8.0 g/dL (moderate), and
<8.0 g/dL (severe), based on the Common
Toxicity Criteria, NCI (14), and the EORTC.
Statistical analyses were based on the pooled
data from all the participating countries. Patient
characteristics and baseline Hb level were exam-
ined with descriptive statistics. Two-way anova
models were used to determine WHO perform-
ance score at enrollment from Hb level at
enrollment, treatment status at enrollment, and
interaction between Hb level and treatment sta-
tus. Additionally, to identify independent risk
factors for anemia, dichotomous potential predic-
tive factors determined a priori (from available
demographic and clinical variables) were evalu-
ated in bivariate analyses with the outcome
measures to obtain unadjusted odds ratios
(ORs) and then entered into a multivariate
logistic regression equation to evaluate the pre-
dictive factors and develop adjusted odds ratios
(AORs). A small diﬀerence between OR and
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379AOR was considered to indicate good independ-
ent predictive power of the predictor in question.
Results
Patients
A total of 15 367 patients were enrolled in ECAS,
of whom 2360 (15.4%) with L/MM are the subject
of this report. Within this subpopulation were 1128
(47.8%) patients with NHL, 512 (21.7%) with HD,
and 720 (30.5%) with MM.
Five patient populations were identiﬁed for
statistical analysis (Fig. 1):
• Enrollment Population (n ¼ 2360): included 720
MM and 1640 L patients, of whom 1128 had
NHL, and 512 had HD. This population was
analyzed for demographics.
• Evaluable Population (n ¼ 2316; 1612 L, 704
MM): excluded 44 ineligible patients with
inconsistent diagnosis and treatment, or retro-
spective data. This population was analyzed for
demographics, Hb levels, prevalence of anemia,
and WHO scores at enrollment.
• Analysis Population (n ¼ 2179; 1514 L, 665
MM): further excluded 137 patients with no
data beyond enrollment. This population was
analyzed for frequency of anemia (prevalence),
WHO scores, and anemia treatment during
ECAS.
• Anemia Chemotherapy Incidence Population
(n ¼ 213; 193 L, 20 MM): included only che-
motherapy patients who were neither anemic
nor receiving anemia treatment at enrollment,
who received their ﬁrst chemotherapy during
ECAS, and underwent at least two chemot-
herapy cycles during the survey. This population
was analyzed for incidence of anemia in L/MM
chemotherapy patients.
• Risk Factor Chemotherapy Population (n ¼
678): included only patients who were neither
anemic nor receiving anemia treatment at en-
rollment, received their ﬁrst chemotherapy dur-
ing ECAS, and underwent at least one
chemotherapy cycle.
Demographics and clinical characteristics of
patients in the Evaluable Population are summar-
ized in Table 1. Of the 2316 patients in this
population at enrollment, 54.0% (1153/2135) were
males and 46.0% (982/2135) were females. The
proportions of males and females were comparable
Fig. 1. Population ﬂowchart for lymphoma/myeloma
ECAS subgroup analysis. L, lymphoma; NHL, non-Hodg-
kin’s lymphoma; HD, Hodgkin’s disease; MM, multiple
myeloma; TX, treatment.








Mean (SD) 57.8 (14.5) 38.1 (15.2) 65.7 (10.9)
Median (range) 60.0 (18–87) 35.0 (18–89) 67.0 (31–94)
Age groups, n (%)
<40 yr 141 (12.8) 304 (61.2) 10 (1.4)
40–59 yr 393 (35.7) 131 (26.4) 185 (26.3)
60–69 yr 314 (28.5) 42 (8.5) 224 (31.8)
‡70 yr 254 (23.0) 20 (4.0) 285 (40.5)
Gender, n (%)
Male 564 (55.9) 257 (53.3) 332 (51.6)
Female 445 (44.1) 225 (46.7) 312 (48.4)
WHO score, n (%)
Grade 0 309 (28.4) 209 (41.9) 129 (18.7)
Grades 1–2 685 (62.9) 276 (55.3) 469 (68.1)
Grades 3–4 95 (8.7) 14 (2.8) 91 (13.2)
Disease status, n (%)
New diagnosis, no treatment 245 (22.3) 143 (28.3) 93 (13.3)
New diagnosis, treatment 247 (22.5) 167 (33.0) 102 (14.6)
P/R 412 (37.5) 100 (19.8) 381 (54.7)
Remission 195 (17.7) 96 (19.0) 121 (17.4)
Treatment status, n (%)
None 474 (43.6) 229 (45.9) 318 (46.2)
Radiotherapy (RT) 15 (1.4) 18 (3.6) 14 (2.0)
Chemotherapy (CT) 595 (54.7) 250 (50.1) 341 (49.5)
Concomitant RT/CT 4 (0.4) 2 (0.4) 16 (2.3)
Hb level (g/dL)
Mean (SD) 12.0 (2.1) 12.6 (1.9) 11.0 (1.9)
Median (range) 12.0 (5.0–17.2) 12.6 (5.6–18.4) 11.0 (5.6–18.1)
Hb category, n (%)
<8.0 g/dL 30 (2.8) 6 (1.2) 31 (4.6)
8.0–9.9 g/dL 157 (14.6) 37 (7.4) 171 (25.1)
10.0–11.9 g/dL 342 (31.7) 144 (28.8) 269 (39.5)
‡12 g/dL 550 (51.0) 313 (62.6) 210 (30.8)
Weight (kg)
Mean (SD) 71.9 (14.3) 71.2 (16.3) 70.7 (15.0)
Median (range) 70.0 (39–150) 68.5 (39–162) 69.0 (35-250)
BMI
Mean (SD) 21.3 (3.7) 20.8 (4.1) 21.3 (4.1)
Median (range) 21.1 (12.7–42.2) 20.0 (12.0–40.0) 20.9 (12.1–78.1)
SD, standard deviation; BMI, body mass index.
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380for the groups with HD and MM; however, the
proportion of males with NHL was slightly higher
than that of females (55.9% vs. 44.1%). The mean
age at enrollment for all L/MM patients (n ¼ 2303)
was 56.0 yr (range 18–94 yr); median age was
59.0 yr. However, the mean age for patients with
HD was substantially lower (38.1 yr) than that for
patients with NHL (57.8 yr) or MM (65.7 yr). In
fact, 61.2% of HD patients were <40 yr of age,
compared with 12.8% of patients with NHL and
1.4% with MM. Conversely, MM occurred more
often in older patients, as demonstrated by 40.5%
of MM patients being ‡70 yr of age, compared with
23.0% and 4.0% of NHL and HD patients,
respectively, being in this age range.
At enrollment, 52.5% (1187/2260) of patients
with L or MM were anemic (Hb <12 g/dL).
Patients with MM were most frequently anemic
(69.2%); 49.0% of patients with NHL were anemic,
as were 37.4% of those with HD. When evaluated
by malignancy, most (28.8–39.5%) patients who
were anemic had Hb levels of 10.0–11.9 g/dL.
However, the prevalence of diﬀerent Hb categories
in patients with the individual diagnoses was not
evenly distributed. As shown in Table 2, low
hemoglobin levels ( £ 9.9 g/dL) were much more
common in patients with MM (29.7%) than in
those with NHL (17.4%) or HD (8.6%).
At enrollment, the majority of patients with MM
had persistent/recurrent disease, whereas the major-
ity of those with NHL or HD were newly diagnosed
(Table 1). Slightly more newly diagnosed patients
with HD than with NHL or MM were receiving
cancer treatment. Treatment status was comparable
across malignancies, with the majority of patients
receiving chemotherapy (49.5–54.7%) or no treat-
ment (43.6–46.2%). Anemia levels categorized by
disease status and treatment status at enrollment
are shown in Table 3. At enrollment, more than
half (58.6%) of patients receiving chemotherapy
were anemic. Anemia was also reported in 42.6% of
patients receiving radiotherapy, and in a similar
proportion of untreated patients (45.4%). Nearly
three-fourths (72.7%) of patients receiving con-
comitant chemotherapy and radiotherapy were
anemic at enrollment; however, this high percent-
age was based on a small population (n ¼ 22).
WHO performance scores
At enrollment, scores indicative of impaired per-
formance (WHO scores of 3 or 4) were recorded for
34.4% of patients with Hb levels <8.0 g/dL, 17.9%
of patients with Hb levels 8.0–9.9 g/dL, and 9.6%
of patients with Hb levels 10.0–11.9 g/dL. This
compares with only 3.4% of patients who were not
anemic (Hb ‡12.0 g/dL). The lowest percentage of
patients with WHO score 0 (18.7%) and the highest
percentage of patients with WHO score 3 or 4
(13.2%) were observed in the MM group, com-
pared with patients in the NHL and HD groups
(Table 1). As shown in Fig. 2, there was a signiﬁ-
cant correlation between mean Hb level and WHO
performance score at enrollment (Spearman r ¼
)0.306, P < 0.001). Signiﬁcant correlations be-
Table 2. Hemoglobin category at enrollment
Hemoglobin category (g/dL)
Diagnostic group
<8.0 8.0–9.9 10.0–11.9 ‡12.0
N % n % n % n %
NHL 30 2.8 157 14.6 342 31.7 550 51.0
HD 6 1.2 37 7.4 144 28.8 313 62.6
MM 31 4.6 171 25.1 269 39.5 210 30.8
NHL, non-Hodgkin's lymphoma; HD, Hodgkin's disease; MM, multiple myeloma.















481 (20.9) 47.0 2.3 14.2 30.5
Newly diagnosed,
with treatment
516 (22.4) 50.1 2.0 14.7 33.5
Persistent/recurrent
disease
893 (38.8) 63.8 5.0 20.9 37.9
In remission 412 (17.9) 37.8 0.8 10.1 26.9
Treatment status
No treatment 1021 (44.9) 45.4 2.4 14.2 28.8
Chemotherapy (CT) 1186 (52.1) 58.6 3.5 17.9 37.2
Radiotherapy (RT) 47 (2.1) 42.6 0 6.4 36.2
Concomitant CT/RT 22 (1.0) 72.7 4.5 36.4 31.8
Fig. 2. Correlation between World Health Organization
(WHO) performance score at enrollment and mean hemo-
globin (Hb) levels (Spearman r ¼ )0.306; P < 0.001).
Anemia in multiple myeloma and lymphoma
381tween mean Hb level and WHO performance score
remained throughout the survey (range: Spearman
r ¼ )0.259 to )0.339; P < 0.001).
Frequency of anemia
The frequency of anemia was determined in
patients who were anemic at any time during
ECAS, including the time of enrollment. Of 2165
patients in the L/MM Analysis Population, 72.9%
experienced anemia at some time during ECAS
(anemia prevalence). Among the three diagnostic
groups, patients with MM were most frequently
anemic (567/665 or 85.3%), followed by patients
with NHL (745/1030 or 77.9%) and those with HD
(271/472 or 57.4%) (Fig. 3). The frequency of
anemia during ECAS categorized by disease status
was 83.7% for patients with persistent/recurrent
disease, 71.6% for patients newly diagnosed and
not receiving treatment, 69.6% for patients newly
diagnosed and receiving treatment, and 54.8% for
those in remission. As shown in Fig. 4, the
frequency of anemia was increased for patients
60 yr of age and older compared with those under
age 60. The anemia that occurred during ECAS was
substantial. More than half (52.0%) of patients
who were anemic at some time during ECAS had
Hb nadirs less than 10.0 g/dL (Fig. 5). Displaying a
pattern similar to that seen at enrollment, patients
with MM were most likely to have Hb nadirs
£ 9.9 g/dL (59.4% vs. 51.5% for patients with
NHL and 37.6% for those with HD).
Incidence of anemia
Two hundred and thirteen chemotherapy patients
fulﬁlled the criteria for inclusion in the Chemo-
therapy Incidence Population. Of these patients,
55.4% became anemic. The incidence of anemia in
chemotherapy patients was greater in the older age
group, i.e., 48.9% in the group under 60 yr of age
became anemic during ECAS compared with
65.9% in the group aged 60 yr and older (Fig. 6).
Anemia treatment
Only 47.3% of L/MM patients who were anemic at
any time during ECAS received treatment for
Fig. 3. Frequency of anemia during ECAS by diagnosis.
Fig. 4. Anemia according to age in patients anemic at any
time during ECAS.
Fig. 5. Nadir hemoglobin (category) for patients anemic at
any time during the European Cancer Anemia Survey
(ECAS), including time of enrollment. Values are provided
for the total L/MM population and patients categorized by
diagnosis.
Fig. 6. Anemia incidence according to age.
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382anemia; 23.9% of these patients had persistent/
recurrent disease, 10.5% were newly diagnosed and
receiving cancer treatment, 8.2% were newly diag-
nosed and not receiving cancer treatment, and
4.8% were in remission. Patients treated for anemia
received one of the following treatments: (i) epoetin
therapy: 23.6% [comprised epoetin alone (9.7%),
epoetin plus transfusion (6.7%), epoetin plus iron
(5.0%), and epoetin plus transfusion and iron
(2.2%)]; (ii) transfusion: 21.0% [comprised trans-
fusion alone (19.4%) and transfusion plus iron
(1.6)]; or (iii) iron alone: 2.8%. Figure 7 shows the
distribution of anemia treatment by disease status.
Anemia treatment was not initiated until Hb levels
were relatively low. The overall Hb nadir for
initiation of anemia treatment was 8.9 g/dL; mean
Hb level for initiation of epoetin was 9.5 g/dL, and
for transfusion was 8.2 g/dL.
Prediction of anemia
The Risk Factor Chemotherapy Population (n ¼
678) was used to determine potential predictors for
the development of anemia. Four dichotomous
variables were found to signiﬁcantly (P < 0.03)
increase the risk for becoming anemic: low initial
Hb, persistent/recurrent disease, female gender, and
treatment with platinum chemotherapy. Table 4
shows the OR and AOR for each of these variables.
The AORs (increase in odds of becoming anemic
when the variables are considered simultaneously)
indicate that females with an initial Hb <12.7 g/dL
and males with an initial Hb <13.3 g/dL have four
times the risk for anemia (Hb levels within-gender
lowest 40th percentile). Persistent/recurrent disease
increases anemia risk 1.5 times, being female
increases anemia risk nearly three times, and
treatment with platinum increases the risk for
anemia 5.5 times. Platinum was administered to
114 patients with L/MM (6.3%); these included 82
of 889 patients with NHL (9.2%), 15 of 394 with
HD (3.8%), and 17 of 519 with MM (3.3%).
Discussion
ECAS is the ﬁrst published prospective survey with
data on anemia in European cancer patients with
L/MM. The survey was conducted to establish a
comprehensive and clinically useful database to
help clarify the complex factors surrounding the
development of cancer-associated anemia (15). Of
the 15 317 patients enrolled in ECAS, 2360 indi-
viduals were patients with L/MM, 2316 of whom
were evaluable.
Analyses of the data for the L/MM subgroup
demonstrated the magnitude of both the prevalence
and the incidence of anemia in this population. At
enrollment, slightly more than half (52.5%) of the
L/MM patients were anemic, the majority of whom
(69.2%) had MM. During ECAS, the frequency of
anemia in the L/MM population rose to 72.9%. As
would be expected, the highest frequency was
observed among patients with MM (85.3%), fol-
lowed by those with NHL (77.9%) and HD
(57.4%), reﬂecting the diﬀerent pathophysiology
of anemia in these three malignancies. The inci-
dence of anemia in L/MM patients, which was
determined in a speciﬁcally deﬁned incidence
group (chemotherapy patients neither anemic nor
receiving anemia treatment at enrollment, ﬁrst
chemotherapy during ECAS, and at least two
chemotherapy cycles during the survey), was found
to be 55.4%. The frequency of anemia during
ECAS, as well as its incidence, was greater in
patients ‡60 yr of age than in patients <60 yr of
age (frequency: 81.1% vs. 65.2%; incidence: 65.9%
vs. 48.9%). This may also partially explain why
anemia was less frequent in patients with HD –
these patients being younger than those in the other
groups. Additionally, it was found that treatment
of cancer-associated anemia in L/MM patients is
often suboptimal, with more than 50% of anemic
patients receiving no treatment.
Taken together, the demonstrated high rate of
anemia in L/MM patients, particularly in elderly
individuals, and suboptimal treatment of anemia in
this population are concerns for several reasons.
First, as with cancer patients in general, anemia
in L/MM patients can lead to fatigue, dyspnea,



















































Fig. 7. Anemia treatment according to disease status.
Table 4. Logistic regression odds ratios for anemia risk
Predictor OR 95% CI P-value AOR 95% CI P-value
Initial Hb
1 3.8 2.76–5.29 <0.0001 4.2 2.99–5.95 <0.0001
P/R disease 1.8 1.31–2.54 <0.0001 1.5 1.05–2.16 0.0276
Female sex 2.4 1.71–3.29 <0.0001 2.8 1.99–4.07 <0.0001
Platinum treatment 4.0 1.72–9.41 0.0006 5.5 2.24–13.54 0.0002
AOR, adjusted odds ratio; CI, confidence interval; Hb, hemoglobin; OR, odds ratio;
P/R, persistent/recurrent disease.
1At enrollment <13.3 g/dL for males; <12.7 g/dL for females.
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383tion, and other symptoms that adversely aﬀect the
patients physical status, functional capacity, and
subsequently, their overall QOL. Studies have
shown that patients living with L or MM and
uncorrected anemia have a poor QOL (15–18).
Fatigue, the primary symptom of anemia, has been
associated with signiﬁcant physical, emotional,
social, and economic consequences that impact
not only the patients, but often their families and/
or primary caretakers as well (19, 20). Fatigue is
especially problematic in the L/MM population, as
many of these patients are older individuals who
typically have a number of comorbidities that are
already straining their physical and mental reserves
and their functional capacity.
Second, anemia may contribute to poorer patient
and therapeutic outcomes, including reduced sur-
vival (2, 11–13). Associations have been found
between low Hb levels and decreased survival in
patients with NHL, HD, mantle cell lymphoma,
chronic lymphocytic leukemia, and Waldenstro ¨ m’s
macroglobulinemia, as well as solid tumors (2, 12,
13, 21–25). Results of a comprehensive review of 60
published papers that reported survival of cancer
patients according to either Hb levels or the
presence of anemia showed that the estimated
increase in risk of death was 65% overall, with a
67% increased risk in anemic patients with lym-
phoma (4). Additionally, anemia may promote
tumor hypoxia, which is thought to impart resist-
ance to irradiation and some chemotherapeutic
agents, and to give rise to malignant progression
(25–27).
Although age and stage of disease have an
impact on QOL, the signiﬁcant (P < 0.001)
correlation shown between WHO performance
scores and mean Hb at enrollment and during
ECAS clearly demonstrated the potential reduction
in QOL that can accompany anemia. However,
cancer-associated anemia can often be corrected,
with resultant improvement in QOL (16–18, 28–
32). Post hoc analysis of prospectively collected
data for a subset of patients with hematologic
malignancies in a randomized placebo-controlled
trial showed that patients treated with the erythro-
poietic stimulating agent epoetin alpha had im-
proved QOL, whereas those treated with placebo
had diminished QOL by most measures [which
included the Functional Assessment of Cancer
Therapy-Anemia (FACT-An) and the Cancer Lin-
ear Analog Scale (CLAS, also known as the Linear
Analog Scale Assessment or LASA)] (18).
Although anemia rates were high for patients
with L or MM in the survey, not all patients
developed anemia. Therefore, data from patients
who were neither anemic at enrollment nor receiv-
ing anemia treatment, received their ﬁrst chemo-
therapy during ECAS, and underwent at least one
(validation population) or two (chemotherapy
incidence population) chemotherapy cycles were
analyzed with logistic regression to ascertain risk
factors for the development of anemia. It was
believed that identifying these factors would enable
clinicians to judge more accurately which patients
are most likely to become anemic so appropriate
anemia management can be initiated in a timely
manner (33). One of the four risk factors identiﬁed
was a low initial Hb level (<13.3 g/dL for men;
<12.7 g/dL for women), the upper limit of which
was within the normal reference range. Platinum
therapy was also identiﬁed as a risk factor,
although platinum chemotherapy is not a usual
treatment for these hematologic malignancies.
However, analyses showed that 114 L/MM patients
(6.3%) received chemotherapy that contained
platinum. The ﬁnding regarding platinum use in
this subset of HM patients was consistent with the
identiﬁcation of platinum use as an anemia risk
factor in the full ECAS population (34). Moreover,
logistic regression analyses have shown that the
cumulative incidence of anemia in patients with
NHL, HL, or MM increases as the number of
chemotherapy cycles they receive as treatment
increases (Table 5). Age was identiﬁed as a signi-
ﬁcant risk factor (P ¼ 0.016) on univariate analy-
sis; however, age was not a signiﬁcant risk factor
(P ¼ 0.46) in the multivariate logistic regression
model in the presence of other predictors. This is
probably because, while the anemia incidence
increases in older patients, the incidence of NHL
and MM also increases in these patients.
Despite high anemia rates and the known detri-
mental eﬀects of anemia and its sequelae on patient
QOL, less than half of the anemic L/MM patients
in the survey received anemia treatment. Similar
proportions of treated patients received transfusion
(21.0%) or epoetin (23.6%). Iron as a single
treatment for anemia was used infrequently
(2.8%). Of note, iron in combination with epoetin
was also used infrequently (5.0%), even though the
Table 5. Cumulative incidence of anemia in patients with increasing numbers of
chemotherapy cycles
Cycle
Total Lymphoma/myeloma groups 123456
Non-Hodgkin's lymphoma Count 12 23 35 38 41 43 69
% 17.4 33.3 50.7 55.1 59.4 62.3 100.0
Hodgkin's lymphoma Count 7 12 15 18 19 20 40
% 17.5 30.0 37.5 45.0 47.5 50.0 100.0
Multiple myeloma Count 2 3 3 3 3 3 4
% 50.0 75.0 75.0 75.0 75.0 75.0 100.0
Total Count 21 38 53 59 63 66 113
% 18.6 33.6 46.9 52.2 55.8 58.4 100.0
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384importance of iron in maintaining adequate iron
stores for erythropoiesis is well-known. Adequate
iron supplies are necessary to support increased
erythropoiesis with epoetin. If epoetin treatment is
successful in increasing Hb levels, iron stores may
be exhausted during the early part of treatment and
a state of iron deﬁciency may be induced. More
often, however, inﬂammatory cytokines associated
with anemia of chronic disease, a frequent causative
factor of cancer-related anemia, may inhibit the
release of iron stores, producing functional iron
deﬁciency, further limiting the rate of red blood cell
production (35, 36). Indeed, more recent data
substantiated this belief and demonstrated the
value of parenteral iron supplementation for
enhancing the response to epoetin (37).
Many clinicians do not initiate anemia treatment
until Hb levels are relatively low. As shown by this
study, the overall Hb nadir for initiation of anemia
treatment in L/MM patients in European commu-
nity practices was 8.9 g/dL. The mean Hb level for
initiation of transfusion was 8.2 g/dL, and for
initiation of epoetin therapy was 9.5 g/dL. The
latter level is lower than the 10 g/dL Hb level
recommended for initiation of erythropoietic sti-
mulating agents (ESAs) in the ASCO-ASH guide-
lines (38). The EORTC guidelines (39), recommend
the initiation of ESA treatment in symptomatic
patients with Hb levels between 9.0 and 11.0 g/dL.
ESA therapy should also be considered in asymp-
tomatic patients in order to prevent further decline
in Hb level, which highlights the importance of
treating anemia before there is a serious decline in
QOL. ECAS data on anemia treatment in L/MM
patients was not suﬃcient to analyze any possible
regional diﬀerences in anemia treatment.
In conclusion, this subgroup analysis of ECAS
data shows that anemia is a widespread and serious
problem among L/MM patients. Supporting this
are the ﬁndings that both the prevalence and the
incidence of anemia in L/MM patients are high,
that anemia is relatively severe (Hb nadir <10.0 g/
dL) in more than half of patients aﬀected, that low
Hb levels are associated with poorer WHO status
(with implications for QOL), and that anemia in
L/MM patients is often untreated. The subgroup
analysis also conﬁrmed the greater likelihood of
patients with MM or NHL to develop anemia,
compared with HD patients. Furthermore, patients
with any of these malignancies who are identiﬁed as
being at high risk for anemia should be followed
carefully to assure timely intervention and optimal
anemia management. The predictive factors and
patterns of anemia treatment in L/MM identiﬁed
by ECAS are important resources that may help
clinicians develop optimal treatment strategies.
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